LeMaitre Vascular (NASDAQ:LMAT) Downgraded by StockNews.com

StockNews.com lowered shares of LeMaitre Vascular (NASDAQ:LMAT) from a buy rating to a hold rating in a report issued on Tuesday morning.

Several other equities analysts have also recently issued reports on LMAT. Roth Capital upgraded shares of LeMaitre Vascular to a strong-buy rating in a research note on Friday, May 31st. Barrington Research lifted their target price on shares of LeMaitre Vascular from $79.00 to $92.00 and gave the company an outperform rating in a research note on Friday, August 2nd. JMP Securities lifted their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a market outperform rating in a report on Tuesday, August 20th. Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They set a buy rating and a $105.00 price target on the stock. Finally, Roth Mkm restated a buy rating and issued a $100.00 target price on shares of LeMaitre Vascular in a report on Friday, May 31st. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, LeMaitre Vascular presently has a consensus rating of Moderate Buy and an average price target of $90.33.

LeMaitre Vascular Stock Down 0.5 %

LMAT opened at $88.62 on Tuesday. The stock has a market cap of $1.99 billion, a PE ratio of 58.69, a P/E/G ratio of 2.63 and a beta of 0.89. The business’s fifty day simple moving average is $84.85 and its 200 day simple moving average is $75.21. LeMaitre Vascular has a 52 week low of $44.27 and a 52 week high of $92.90.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The firm had revenue of $55.85 million for the quarter, compared to analysts’ expectations of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.63%. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.37 earnings per share. As a group, equities analysts anticipate that LeMaitre Vascular will post 1.77 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, August 29th. Investors of record on Thursday, August 15th were paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.72%. The ex-dividend date of this dividend was Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Insider Transactions at LeMaitre Vascular

In related news, Director David B. Roberts sold 3,063 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the sale, the director now directly owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO George W. Lemaitre sold 12,976 shares of LeMaitre Vascular stock in a transaction on Friday, July 12th. The shares were sold at an average price of $86.07, for a total transaction of $1,116,844.32. Following the sale, the chief executive officer now directly owns 1,985,358 shares in the company, valued at approximately $170,879,763.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David B. Roberts sold 3,063 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the transaction, the director now directly owns 14,114 shares in the company, valued at $1,158,335.98. The disclosure for this sale can be found here. Insiders have sold a total of 43,251 shares of company stock worth $3,714,994 in the last quarter. Company insiders own 10.79% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mesirow Institutional Investment Management Inc. acquired a new position in shares of LeMaitre Vascular during the 4th quarter worth approximately $8,837,000. Driehaus Capital Management LLC boosted its stake in shares of LeMaitre Vascular by 52.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after purchasing an additional 90,573 shares during the last quarter. F M Investments LLC acquired a new stake in LeMaitre Vascular during the second quarter worth approximately $7,443,000. Congress Asset Management Co. MA grew its holdings in LeMaitre Vascular by 17.0% in the 4th quarter. Congress Asset Management Co. MA now owns 594,672 shares of the medical instruments supplier’s stock valued at $33,754,000 after buying an additional 86,293 shares during the period. Finally, Summit Creek Advisors LLC grew its holdings in LeMaitre Vascular by 37.8% in the fourth quarter. Summit Creek Advisors LLC now owns 228,501 shares of the medical instruments supplier’s stock valued at $12,970,000 after purchasing an additional 62,737 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.